The Asia-Pacific (APAC) region has become a leading destination for oncology clinical trials, seeing a 138% increase from 2010 to 2020. Key factors include a high patient population, skilled personnel, and lower costs. APAC is home to many treatment-naïve patients and growing middle class willing to participate in trials. Regulatory compliance is relatively easy, and the region boasts top clinical institutions and key opinion leaders. Improvements in data quality and a rise in novel drug development further drive growth. The shift to decentralized trials, spurred by COVID-19, and strong local innovation, particularly in China and Korea, also contribute to this trend.

Join for free to read